Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome

Area of Science:

• Oncology
• Dermatology
• Hematology

Background:

• Sézary syndrome (SS) treatment options are limited with low response rates.
• Brentuximab vedotin is an approved CD30-directed therapy for refractory CD30-positive cutaneous T-cell lymphoma.
• Limited data exist on brentuximab vedotin's efficacy in SS.

Purpose of the Study:

• To assess the preliminary efficacy and tolerability of brentuximab vedotin in patients with Sézary syndrome.
• Evaluate response rates across skin, blood, and lymph nodes.
• Document adverse events associated with brentuximab vedotin treatment in SS.

Main Methods:

• Retrospective case series of 13 SS patients treated with brentuximab vedotin.
• Median follow-up of 10.4 months.
• Response assessed using established criteria for skin, lymph nodes, and blood involvement.

Main Results:

• A global response rate of 38% was observed, including one complete response.
• Response rates were 38% in skin, 63% in blood, and 50% in lymph nodes.
• Peripheral neuropathy occurred in 4 patients, with 2 resolving; other adverse events were generally low grade.

Conclusions:

• Brentuximab vedotin demonstrated preliminary efficacy in SS across multiple disease compartments.
• The therapy may be a viable option for refractory SS, even with low CD30 expression.
• Brentuximab vedotin offers a manageable treatment schedule with a low incidence of significant toxic effects.